Waldmann Discusses the "The Second Coming of Daclizumab"

Posted: Aug 24, 2016

Dr. Waldmann discusses his 35-year odyssey with daclizumab.
Read more...

Waldmann Discusses the "The Second Coming of Daclizumab"

Blood-Brain Barrier: The "Holy Grail' of Neuro-oncology

Posted: Aug 24, 2016

"People like me say…we need to find a way…"  Sadhana Jackson, a physician researcher with the Neuro-Oncology Branch, discusses the challenges of delivering drug treatments to brain tumors in an interview with HemOnc Today. Read More...

Blood-Brain Barrier: The "Holy Grail' of Neuro-oncology

Dr. Ramaprasad Srinivasan Appointed as Tenure Track Investigator

Posted: Aug 23, 2016

Ramaprasad Srinivasan, M.D., Ph.D., has been appointed as a Tenure Track Investigator in the Urologic Oncology Branch. Dr. Srinivasan is a recognized expert in genitourinary oncology, notably in targeted therapeutic approaches for patients with advanced forms of renal cell carcinoma. His research focuses on developing and conducting clinical trials using molecular treatment approaches targeting kidney cancer pathways and targeted therapeutic agents in patients with localized and advanced forms of kidney cancer. He is currently investigating a variety of newer targeted agents in clear cell and papillary kidney cancer, as well as hereditary kidney cancer syndromes, such as von Hippel-Lindau, hereditary leiomyomatosis, and renal cell cancer and hereditary papillary renal cell cancer.

Dr. Ramaprasad Srinivasan Appointed as Tenure Track Investigator

Seeking to Unlock the Genomic Keys to Ovarian Cancer

Posted: Aug 22, 2016

CCR’s Tina Annunziata, physician scientist with the Women’s Malignancies Branch discusses genomic profiling in ovarian cancer in an interview in OncLive Read more...

Seeking to Unlock the Genomic Keys to Ovarian Cancer

Faith, Hope, and Determination Help Teenager Fight A Rare Cancer

Posted: Aug 19, 2016

Our clinical research is not possible without exceptional people like teenager, Terran Dupree, who is enrolled on a mesothelioma clinical trial in CCR’s Pediatric Oncology Branch. Physician-scientist Rosie Kaplan calls Terran “a strong, beautiful young lady with a big open heart.”   Read More...

Faith, Hope, and Determination Help Teenager Fight A Rare Cancer

Clinical Trials on Pets Moving Cancer Research Forward

Posted: Aug 19, 2016

Science magazine profiled CCR’s Comparative Oncology Program, which coordinates a nationwide network of veterinary oncologists running clinical trials with pet animals suffering with cancer. Read More...

Clinical Trials on Pets Moving Cancer Research Forward

New Immunotherapy Gives Tumor-Fighting Immune Cells the Chance to Attack

Posted: Aug 18, 2016

Scientists at the National Cancer Institute’s Center for Cancer Research have empowered the immune systems of mice to rid their bodies of tumors with a new kind of immunotherapy.

New Immunotherapy Gives Tumor-Fighting Immune Cells the Chance to Attack

Tanner Named as One of the 2016 Young Innovators of Cellular and Molecular Bioengineering

Posted: Aug 17, 2016

Kandice Tanner was selected as one of the 2016 Cellular and Molecular Bioengineering (CMBE) Young Innovators. She will present her work on the mechanical properties of the tumor stromal microenvironment at the 2016 Annual Biomedical Engineering Society Meeting in Minneapolis, Minnesota on October 5–8, 2016.

Tanner Named as One of the 2016 Young Innovators of Cellular and Molecular Bioengineering

Ramiro Iglesias-Bartolome Joins CCR as a Stadtman Investigator

Posted: Aug 9, 2016

Ramiro Iglesias-Bartolome has joined CCR as a Stadtman Tenure Track Investigator in the Laboratory of Cellular and Molecular Biology (LCMB).  Dr. Iglesias-Bartolome’s research focuses on identifying GPCRs that are expressed in epithelial stem cells and that regulate their proliferation and differentiation; identifying and studying heterotrimeric G proteins coupled to the GPCRs; and identifying and characterizing cytoplasmic and nuclear events downstream of the GPCRs and G proteins. 

Ramiro Iglesias-Bartolome Joins CCR as a Stadtman Investigator

PARP Inhibitors May Affect Normal Cells in Patients with a BRCA Mutation

Posted: Aug 8, 2016

PARP inhibition has been approved for treatment of advanced ovarian cancer with BRAC1 and BRAC2 mutations and is being studied in the treatment advanced breast, colorectal, and prostate cancer.  A new study by Center for Cancer Research scientists in the Mouse Cancer Genetics Program and the Laboratory of Genome Integrity, raises concerns that when cancer patients with a BRCA mutation are treated with PARP inhibitors their normal cells may also be affected.  

PARP Inhibitors May Affect Normal Cells in Patients with a BRCA Mutation

Pages